Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rui You

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Cancer Communications (London, England)|November 16, 2019
Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinomaYou-Ping Liu, Xing Lv, Xiong Zou, et al.
Oncotarget|December 5, 2015
Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients' survivalRou Jiang, Rui You, Xiao-Qing Pei, et al.
Oral Oncology|May 1, 2018
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinomaMei Lin, Rui You, You-Ping Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II StudyXi Ding, Wei-Jing Zhang, Rui You, et al.
Theranostics|July 26, 2017
Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-upRui You, Yi-Jun Hua, You-Ping Liu, et al.
International Journal of Cancer|June 4, 2017
Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinomaRui You, Rui Sun, Yi-Jun Hua, et al.
Theranostics|May 17, 2021
Neoantigen landscape in metastatic nasopharyngeal carcinomaMei Lin, Xiao-Long Zhang, Rui You, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective studyMeng-Xia Zhang, Ting Liu, Rui You, et al.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2017
Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatmentXiong Zou, Rui You, Huai Liu, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Cancer Communications (London, England)|November 16, 2019
Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinomaYou-Ping Liu, Xing Lv, Xiong Zou, et al.
Oncotarget|December 5, 2015
Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients' survivalRou Jiang, Rui You, Xiao-Qing Pei, et al.
Oral Oncology|May 1, 2018
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinomaMei Lin, Rui You, You-Ping Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II StudyXi Ding, Wei-Jing Zhang, Rui You, et al.
Theranostics|July 26, 2017
Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-upRui You, Yi-Jun Hua, You-Ping Liu, et al.
International Journal of Cancer|June 4, 2017
Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinomaRui You, Rui Sun, Yi-Jun Hua, et al.
Theranostics|May 17, 2021
Neoantigen landscape in metastatic nasopharyngeal carcinomaMei Lin, Xiao-Long Zhang, Rui You, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective studyMeng-Xia Zhang, Ting Liu, Rui You, et al.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2017
Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatmentXiong Zou, Rui You, Huai Liu, et al.
Pageof 18